Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, provides a trading update which reflects lower than expected revenue,
Avacta Group PLC (AIM:AVCT) Successful Completion of Fourth Dose Escalation
Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study
Omega Diagnostics Gp (AIM:ODX) US expansion update
Maiden US Laboratory FoodPrint® installation,
Abingdon Health PLC (AIM:ABDX) Award of Options under new LTIP Scheme
York, U.K. 19 December 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality, rapid diagnostic tests, announces the establishment of a new Long Term Incentive Plan
Novacyt S.A. (AIM:NCYT) Approval of genesig COVID-19 3G PCR test in UK
Approval of genesig® COVID-19 3G PCR test in the UK under CTDA legislation
Abingdon Health PLC (AIM:ABDX) Preliminary Results
York, U.K. 24 November 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality, rapid diagnostic tests, announces its preliminary results for the year ended
Avacta Group PLC (AIM:AVCT) Avacta to Present at Theranostics FAP Summit
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms.
Novacyt S.A. (AIM:NCYT) UK Approval of genesig® SARS-CoV-2 Winterplex® 3G
A multiplex PCR test for the detection of winter viruses including SARS-CoV-2, influenza A and B, and RSV
Avacta Group PLC (AIM:AVCT) Proposed acquisition of Launch Diagnostics
Launch Diagnostics is a leading independent distributor in the UK in-vitro diagnostics (IVD) market
Abingdon Health PLC (AIM:ABDX) Further re. Outcome of Judicial Review
All grounds were dismissed, including the claim of state aid, apparent bias and national preference
Abingdon Health PLC (AIM:ABDX) Outcome of Judicial Review – All claims brought by GLP dismissed
York, U.K. 7 October 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality, rapid diagnostic tests, notes the judgement by Mr Justice Waksman in